Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
BNT327
i
Other names:
BNT 327, BNT-327, BNT327, PM8002, PM 8002, PM-8002
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(2)
News
Trials
Company:
BioNTech, Biotheus
Drug class:
PD-L1 inhibitor, VEGF-A inhibitor
Related drugs:
‹
atezolizumab (236)
durvalumab (199)
avelumab (89)
KN046 (19)
benmelstobart (12)
M7824 (9)
sugemalimab (7)
envafolimab (6)
SHR-1701 (6)
IO102-IO103 (4)
MT-6402 (2)
SAR445710 (2)
socazolimab (2)
BMS-202 (1)
CCX559 (1)
EPIM-001 (1)
FS118 (1)
GI-101 (1)
INCB86550 (1)
NI-2901 (1)
PM1003 (1)
Q-1802 (1)
atezolizumab and hyaluronidase-tqjs (1)
LY3300054 (1)
GNC-035 (1)
6MW3211 (0)
AB-101 (0)
ABL501 (0)
ABSK043 (0)
AP203 (0)
ASC61 (0)
ATG-027 (0)
AUR-106 (0)
adebrelimab (0)
BMS-936559 (0)
BPB-101 (0)
BPI-371153 (0)
BS006 (0)
CA-170 (0)
CARG-2020 (0)
CDR101 (0)
CDX-527 (0)
CF33-hNIS-antiPDL1 (0)
DSP502 (0)
FS222 (0)
GB266 (0)
GNC-039 (0)
HB0036 (0)
HK010 (0)
IBC0966 (0)
IBI-323 (0)
IMC-001 (0)
IMC-201 (0)
IMM2505 (0)
IMM2520 (0)
IMMH-010 (0)
INCB99280 (0)
IO103 (0)
KY1043 (0)
LAE005 (0)
LB101 (0)
LP002 (0)
LY3415244 (0)
MCLA-145 (0)
NI-2601 (0)
NM21-1480 (0)
PD-L1.t-haNK (0)
PF-07257876 (0)
PM1022 (0)
PM8001 (0)
QL301 (0)
RC98 (0)
S095025 (0)
SIM0237 (0)
TQB2858 (0)
TST005 (0)
Undisclosed anti-PD-L1 antibody (0)
cosibelimab-ipdl (0)
VG161 (0)
GEN1046 (0)
MSB2311 (0)
GNC-038 (0)
GS-4224 (0)
BC003 (0)
mRNA-4359 (0)
HLX20 (0)
CX-072 (0)
ABL503 (0)
IBI318 (0)
IBI-322 (0)
HBM9167 (0)
bevacizumab (416)
Aybintio (bevacizumab biosimilar) (14)
bevacizumab-maly (12)
bevacizumab-awwb (11)
bevacizumab-adcd (11)
bevacizumab-tnjn (8)
bevacizumab-bvzr (8)
aflibercept intravitreal (7)
Krabeva (bevacizumab biosimilar) (7)
Byvasda (bevacizumab biosimilar) (4)
ziv-aflibercept IV (4)
CTX-009 (1)
SIBP-04 (bevacizumab biosimilar) (1)
BP102 (bevacizumab biosimilar) (0)
SCT510 (bevacizumab biosimilar) (0)
Ankada (bevacizumab biosimilar) (0)
BI 695502 (bevacizumab biosimilar) (0)
MIL 60 (bevacizumab biosimilar) (0)
LY01008 (bevacizumab biosimilar) (0)
CBT124 (bevacizumab biosimilar) (0)
Cizumab (bevacizumab biosimilar) (0)
Equidacent (bevacizumab biosimilar) (0)
GB222 (bevacizumab biosimilar) (0)
GZ402663 (0)
HLX-04 (bevacizumab biosimilar) (0)
LYN-00101 (0)
ranibizumab (0)
MP0250 (0)
MSB0254 (0)
Onbevzi (bevacizumab biosimilar) (0)
PB101 (0)
Pusintin (bevacizumab biosimilar) (0)
TRS003 (bevacizumab biosimilar) (0)
HD204 (bevacizumab biosimilar) (0)
CLS-AX (0)
bevacizumab biosimilar (0)
hVEGF26–104/RFASE (0)
APX003 (0)
atezolizumab (236)
durvalumab (199)
avelumab (89)
KN046 (19)
benmelstobart (12)
M7824 (9)
sugemalimab (7)
envafolimab (6)
SHR-1701 (6)
IO102-IO103 (4)
MT-6402 (2)
SAR445710 (2)
socazolimab (2)
BMS-202 (1)
CCX559 (1)
EPIM-001 (1)
FS118 (1)
GI-101 (1)
INCB86550 (1)
NI-2901 (1)
PM1003 (1)
Q-1802 (1)
atezolizumab and hyaluronidase-tqjs (1)
LY3300054 (1)
GNC-035 (1)
6MW3211 (0)
AB-101 (0)
ABL501 (0)
ABSK043 (0)
AP203 (0)
ASC61 (0)
ATG-027 (0)
AUR-106 (0)
adebrelimab (0)
BMS-936559 (0)
BPB-101 (0)
BPI-371153 (0)
BS006 (0)
CA-170 (0)
CARG-2020 (0)
CDR101 (0)
CDX-527 (0)
CF33-hNIS-antiPDL1 (0)
DSP502 (0)
FS222 (0)
GB266 (0)
GNC-039 (0)
HB0036 (0)
HK010 (0)
IBC0966 (0)
IBI-323 (0)
IMC-001 (0)
IMC-201 (0)
IMM2505 (0)
IMM2520 (0)
IMMH-010 (0)
INCB99280 (0)
IO103 (0)
KY1043 (0)
LAE005 (0)
LB101 (0)
LP002 (0)
LY3415244 (0)
MCLA-145 (0)
NI-2601 (0)
NM21-1480 (0)
PD-L1.t-haNK (0)
PF-07257876 (0)
PM1022 (0)
PM8001 (0)
QL301 (0)
RC98 (0)
S095025 (0)
SIM0237 (0)
TQB2858 (0)
TST005 (0)
Undisclosed anti-PD-L1 antibody (0)
cosibelimab-ipdl (0)
VG161 (0)
GEN1046 (0)
MSB2311 (0)
GNC-038 (0)
GS-4224 (0)
BC003 (0)
mRNA-4359 (0)
HLX20 (0)
CX-072 (0)
ABL503 (0)
IBI318 (0)
IBI-322 (0)
HBM9167 (0)
bevacizumab (416)
Aybintio (bevacizumab biosimilar) (14)
bevacizumab-maly (12)
bevacizumab-awwb (11)
bevacizumab-adcd (11)
bevacizumab-tnjn (8)
bevacizumab-bvzr (8)
aflibercept intravitreal (7)
Krabeva (bevacizumab biosimilar) (7)
Byvasda (bevacizumab biosimilar) (4)
ziv-aflibercept IV (4)
CTX-009 (1)
SIBP-04 (bevacizumab biosimilar) (1)
BP102 (bevacizumab biosimilar) (0)
SCT510 (bevacizumab biosimilar) (0)
Ankada (bevacizumab biosimilar) (0)
BI 695502 (bevacizumab biosimilar) (0)
MIL 60 (bevacizumab biosimilar) (0)
LY01008 (bevacizumab biosimilar) (0)
CBT124 (bevacizumab biosimilar) (0)
Cizumab (bevacizumab biosimilar) (0)
Equidacent (bevacizumab biosimilar) (0)
GB222 (bevacizumab biosimilar) (0)
GZ402663 (0)
HLX-04 (bevacizumab biosimilar) (0)
LYN-00101 (0)
ranibizumab (0)
MP0250 (0)
MSB0254 (0)
Onbevzi (bevacizumab biosimilar) (0)
PB101 (0)
Pusintin (bevacizumab biosimilar) (0)
TRS003 (bevacizumab biosimilar) (0)
HD204 (bevacizumab biosimilar) (0)
CLS-AX (0)
bevacizumab biosimilar (0)
hVEGF26–104/RFASE (0)
APX003 (0)
›
Associations
(2)
News
Trials
VERI cancer hierarchy
Reset Filters
PD-L1 expression
Triple Negative Breast Cancer
PD-L1 expression
Triple Negative Breast Cancer
BNT327
Sensitive: C2 – Inclusion Criteria
BNT327
Sensitive
:
C2
BNT327
Sensitive: C2 – Inclusion Criteria
BNT327
Sensitive
:
C2
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
BNT327
Sensitive: C3 – Early Trials
BNT327
Sensitive
:
C3
BNT327
Sensitive: C3 – Early Trials
BNT327
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login